dalteparin has been researched along with Arterial Obstructive Diseases in 28 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study showed no superiority of low-molecular-weight heparin (LMWH) over aspirin for the primary end point (Barthel Index) in acute ischemic stroke due to large artery occlusive disease." | 9.16 | Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, QS; Wong, KS, 2012) |
| " We present a unique case of ET causing extensive arterial thromboembolism, despite being on adequate antithrombotic agents including warfarin and aspirin." | 7.85 | Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ( Ahmed, AK; Skeik, N; Youssef, A, 2017) |
| "Warfarin-induced skin necrosis is a rare complication associated with the use of oral anticoagulants." | 7.72 | A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency. ( Alexander, JB; Ierardi, R; Tai, CY, 2004) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 5.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "The Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study showed no superiority of low-molecular-weight heparin (LMWH) over aspirin for the primary end point (Barthel Index) in acute ischemic stroke due to large artery occlusive disease." | 5.16 | Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, QS; Wong, KS, 2012) |
| "After successful PTA, 275 patients with symptomatic peripheral arterial disease (claudication or critical limb ischemia) and femoropopliteal obstructions were randomized to receive either 2500 IU of dalteparin subcutaneously for 3 months plus 100 mg of aspirin daily (n = 137), or 100 mg aspirin daily alone (n = 138)." | 5.12 | Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial. ( Amann-Vesti, BR; Banyai, M; Koppensteiner, R; Meier, T; Pfammatter, T; Rousson, V; Spring, S; van der Loo, B, 2006) |
| "We report a case of ophthalmic artery occlusion (OAO) in a young patient with COVID-19 infection that was on therapeutic anticoagulation with apixaban for deep venous thrombosis (DVT)." | 3.96 | Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban. ( Biousse, V; Bose, S; Dumitrascu, OM; Lyden, PD; Volod, O; Wang, Y, 2020) |
| " We present a unique case of ET causing extensive arterial thromboembolism, despite being on adequate antithrombotic agents including warfarin and aspirin." | 3.85 | Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ( Ahmed, AK; Skeik, N; Youssef, A, 2017) |
| "Warfarin-induced skin necrosis is a rare complication associated with the use of oral anticoagulants." | 3.72 | A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency. ( Alexander, JB; Ierardi, R; Tai, CY, 2004) |
| " The general use and correct dosage of low-molecular-weight heparin, however, are still under debate." | 2.70 | Low-molecular-weight heparin in arterial reconstructive surgery: a double-blind, randomized dose-finding trial. ( Eckmann, C; Kujath, P; Misselwitz, F, 2002) |
| "BACKGROUND Coronavirus disease 2019 (COVID-19) has a tremendous impact on the respiratory tract." | 1.72 | A Patient-Tailored Approach to Management of Acute Limb Ischemia in Patients with COVID-19: A Case Series. ( AlGhofili, H; Alhumaid, A; Aljabri, B; Altoijry, A; Iqbal, K, 2022) |
| " In the patients of both groups the product dabigatran etexilate in the standard dosage (220 mg/day) was used for specific prevention." | 1.43 | [Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities]. ( Akhtyamov, IF; Shigaev, ES; Ziatdinov, BG, 2016) |
| " Protocols vary from center to center, but there is still no consensus regarding the proper dosage or treatment duration." | 1.42 | The Use of Low-Dose Recombinant Tissue Plasminogen Activator to Treat a Preterm Infant with an Intrauterine Spontaneous Arterial Thromboembolism. ( Caner, İ; Demirelli, Y; Kara, M; Tekgündüz, KŞ, 2015) |
| "Acute pulmonary embolism is an important emergency disease which frequently results in life-threatening complication." | 1.39 | Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus. ( Acar, RD; Karakoyun, S; Ozkan, M; Yildiz, M, 2013) |
| "Dabigatran was stopped and dalteparin 5000 International Units/bid and 40 μg alprostadil infusions were started." | 1.38 | Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy. ( Finsterer, J; Reiter, M; Schäffl-Doweik, L; Stöllberger, C, 2012) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 1.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 12 (42.86) | 29.6817 |
| 2010's | 13 (46.43) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Bang, OY | 1 |
| Kim, JS | 1 |
| Wang, QS | 1 |
| Chen, C | 2 |
| Chen, XY | 1 |
| Han, JH | 1 |
| Soo, Y | 1 |
| Leung, TW | 1 |
| Mok, V | 1 |
| Wong, KS | 2 |
| Mazzone, A | 1 |
| Giani, L | 1 |
| Faggioli, P | 1 |
| Pichini, S | 1 |
| Pacifici, R | 1 |
| Ng, PW | 1 |
| Tsoi, TH | 1 |
| Li, HL | 1 |
| Fong, WC | 1 |
| Yeung, J | 1 |
| Wong, CK | 1 |
| Yip, KK | 1 |
| Gao, H | 1 |
| Wong, HB | 1 |
| Schweizer, J | 1 |
| Müller, A | 1 |
| Forkmann, L | 1 |
| Hellner, G | 1 |
| Kirch, W | 1 |
| Camporese, G | 1 |
| Bernardi, E | 1 |
| Noventa, F | 1 |
| Alhumaid, A | 1 |
| Altoijry, A | 1 |
| Aljabri, B | 1 |
| Iqbal, K | 1 |
| AlGhofili, H | 1 |
| Dumitrascu, OM | 1 |
| Volod, O | 1 |
| Bose, S | 1 |
| Wang, Y | 1 |
| Biousse, V | 1 |
| Lyden, PD | 1 |
| Demirelli, Y | 1 |
| Tekgündüz, KŞ | 1 |
| Caner, İ | 1 |
| Kara, M | 1 |
| Beato, J | 1 |
| Fígueira, L | 1 |
| Penas, S | 1 |
| Santos-Silva, R | 1 |
| Falcão, M | 1 |
| Carneiro, Â | 1 |
| Reis, FF | 1 |
| Akhtyamov, IF | 1 |
| Ziatdinov, BG | 1 |
| Shigaev, ES | 1 |
| Ahmed, AK | 1 |
| Youssef, A | 1 |
| Skeik, N | 1 |
| Feray, H | 1 |
| Izgi, C | 1 |
| Cetiner, D | 1 |
| Men, EE | 1 |
| Saltan, Y | 1 |
| Baltay, A | 1 |
| Kahraman, R | 1 |
| Raynaud, A | 1 |
| Novelli, L | 1 |
| Rovani, X | 1 |
| Carreres, T | 1 |
| Bourquelot, P | 1 |
| Hermelin, A | 1 |
| Angel, C | 1 |
| Beyssen, B | 1 |
| Duschek, N | 1 |
| Vafaie, M | 1 |
| Skrinjar, E | 1 |
| Hirsch, K | 1 |
| Waldhör, T | 1 |
| Hübl, W | 1 |
| Bergmayr, W | 1 |
| Knoebl, P | 1 |
| Assadian, A | 1 |
| Stöllberger, C | 1 |
| Reiter, M | 1 |
| Schäffl-Doweik, L | 1 |
| Finsterer, J | 1 |
| Yildiz, M | 1 |
| Karakoyun, S | 1 |
| Acar, RD | 1 |
| Ozkan, M | 1 |
| Tai, CY | 1 |
| Ierardi, R | 1 |
| Alexander, JB | 1 |
| Hans, GA | 1 |
| Senard, M | 1 |
| Ledoux, D | 1 |
| Grayet, B | 1 |
| Scholtes, F | 1 |
| Creemers, E | 1 |
| Lamy, ML | 1 |
| Kujath, P | 1 |
| Eckmann, C | 1 |
| Misselwitz, F | 1 |
| Göttman, D | 1 |
| Strecker, EP | 1 |
| Boos, I | 1 |
| Vetter, S | 1 |
| Skeppholm, M | 1 |
| Kallner, A | 1 |
| Kalani, M | 2 |
| Jörneskog, G | 2 |
| Blombäck, M | 2 |
| Wallén, HN | 1 |
| Pokrovskiĭ, AV | 1 |
| Gontarenko, VN | 1 |
| Titova, MI | 1 |
| Apelqvist, J | 1 |
| Brismar, K | 1 |
| Eliasson, B | 1 |
| Eriksson, JW | 1 |
| Fagrell, B | 1 |
| Hamsten, A | 1 |
| Torffvit, O | 1 |
| Kovacs, MJ | 1 |
| Kearon, C | 1 |
| Rodger, M | 1 |
| Anderson, DR | 1 |
| Turpie, AG | 1 |
| Bates, SM | 1 |
| Desjardins, L | 1 |
| Douketis, J | 1 |
| Kahn, SR | 1 |
| Solymoss, S | 1 |
| Wells, PS | 1 |
| Koppensteiner, R | 1 |
| Spring, S | 1 |
| Amann-Vesti, BR | 1 |
| Meier, T | 1 |
| Pfammatter, T | 1 |
| Rousson, V | 1 |
| Banyai, M | 1 |
| van der Loo, B | 1 |
| Telen, MJ | 1 |
| Batchvarova, M | 1 |
| Shan, S | 1 |
| Bovee-Geurts, PH | 1 |
| Zennadi, R | 1 |
| Leitgeb, A | 1 |
| Brock, R | 1 |
| Lindgren, M | 1 |
| Megalopoulos, A | 1 |
| Vasiliadis, K | 1 |
| Tsachalis, T | 1 |
| Tsalis, K | 1 |
| Blouhos, K | 1 |
| Alexandridou, S | 1 |
| Betsis, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for dalteparin and Arterial Obstructive Diseases
| Article | Year |
|---|---|
Update on the clinical use of the low-molecular-weight heparin, parnaparin.
Topics: Acute Coronary Syndrome; Anticoagulants; Arterial Occlusive Diseases; Cardiovascular Diseases; Drug | 2009 |
[Administration of dalteparin in reconstructive vascular surgery].
Topics: Anticoagulants; Arterial Occlusive Diseases; Arteries; Blood Coagulation; Blood Coagulation Factors; | 2011 |
9 trials available for dalteparin and Arterial Obstructive Diseases
| Article | Year |
|---|---|
Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arterial Occlusive Diseases; As | 2012 |
Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; A | 2007 |
Potential use of a low-molecular-weight heparin to prevent restenosis in patients with extensive wall damage following peripheral angioplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive | 2001 |
Comparison of enoxaparin and unfractionated heparin in endovascular interventions for the treatment of peripheral arterial occlusive disease: a randomized controlled trial.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Drug Therapy, Combination; Endothelium, Vascular; Enoxap | 2011 |
Low-molecular-weight heparin in arterial reconstructive surgery: a double-blind, randomized dose-finding trial.
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Blood Vessel Prosthesis Implantation; Dose-Respon | 2002 |
[Dose-dependent decrease of the rate of restenosis of stents in peripheral vessels with reviparin].
Topics: Aged; Angiography, Digital Subtraction; Anticoagulants; Arterial Occlusive Diseases; Dose-Response R | 1999 |
Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Age of Onset; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Body Mass Index; Dalteparin; Dia | 2003 |
Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin.
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Atrial Fibrillation; Blood Loss, Surgical; Coh | 2004 |
Low-molecular-weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Dalteparin; Drug Therapy, Combinat | 2006 |
17 other studies available for dalteparin and Arterial Obstructive Diseases
| Article | Year |
|---|---|
Low-molecular-weight heparin in atherosclerotic stroke: a surprising resurrection of anticoagulants?
Topics: Antifibrinolytic Agents; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Female; Humans; Intra | 2012 |
Cocaine-related peripheral vascular occlusive disease treated with iloprost in addition to anticoagulants and antibiotics.
Topics: Acute Disease; Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anticoag | 2007 |
A Patient-Tailored Approach to Management of Acute Limb Ischemia in Patients with COVID-19: A Case Series.
Topics: Adult; Aged; Arterial Occlusive Diseases; COVID-19; Enoxaparin; Female; Humans; Ischemia; Male; Midd | 2022 |
Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban.
Topics: Arterial Occlusive Diseases; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatm | 2020 |
The Use of Low-Dose Recombinant Tissue Plasminogen Activator to Treat a Preterm Infant with an Intrauterine Spontaneous Arterial Thromboembolism.
Topics: Arterial Occlusive Diseases; Brachial Artery; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2015 |
Presumed bilateral cilioretinal artery occlusion related to relapsing white dot syndrome.
Topics: Arterial Occlusive Diseases; Aspirin; Ciliary Arteries; Coloring Agents; Drug Therapy, Combination; | 2016 |
[Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities].
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Arthroplasty, Replacement, Hip; Blood Coagulation | 2016 |
Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure.
Topics: Anticoagulants; Arterial Occlusive Diseases; Blood Coagulation; Blood Coagulation Tests; Computed To | 2017 |
Effectiveness of enoxaparin for prevention of radial artery occlusion after transradial cardiac catheterization.
Topics: Arterial Occlusive Diseases; Cardiac Catheterization; Enoxaparin; Female; Follow-Up Studies; Humans; | 2010 |
Radiocephalic fistula complicated by distal ischemia: treatment by ulnar artery dilatation.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Catheters, Indwelling; Clopidogrel; Diabete | 2010 |
Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy.
Topics: Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Benzimidazole | 2012 |
Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus.
Topics: Acute Disease; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; Drug Substitution; Em | 2013 |
A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency.
Topics: Anticoagulants; Arterial Occlusive Diseases; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-M | 2004 |
Cerebral subarachnoid blood migration consecutive to a lumbar haematoma after spinal anaesthesia.
Topics: Aged; Anesthesia, Spinal; Anesthetics, Intravenous; Anesthetics, Local; Angioplasty, Balloon; Arteri | 2008 |
ADAMTS13 and von Willebrand factor concentrations in patients with diabetes mellitus.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Case-C | 2009 |
Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion.
Topics: Anemia, Sickle Cell; Animals; Arterial Occlusive Diseases; Cell Adhesion; Cells, Cultured; Endotheli | 2016 |
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen | 2006 |